Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations
Open Access
- 1 January 2002
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (2) , 218-221
- https://doi.org/10.1038/sj.bjc.6600064
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studyThe Lancet, 2000
- Novel indications forBRCA1 screening using individual clinical and morphological featuresInternational Journal of Cancer, 1999
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriersOncogene, 1998
- Tumour biological features of BRCA1-induced breast and ovarian cancerEuropean Journal Of Cancer, 1997
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Re: Second Cancers After Adjuvant Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trialBreast Cancer Research and Treatment, 1986